ArticleThe Journal of infectious diseases2011
Smallpox vaccine safety is dependent on T cells and not B cells.
Article in The Journal of infectious diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06223919 (Randomized Trial to Evaluate the Efficacy/Effectiveness, Safety, and Immunogenicity of Replicative Live Attenuated Vaccinia Virus Vaccine LC16m8 for Prevention Against Mpox in High-risk Populations During Vaccination Deployment in Colombia), which is not on this map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Trial to Evaluate the Efficacy/Effectiveness, Safety, and Immunogenicity of Replicative Live Attenuated Vaccinia Virus Vaccine LC16m8 for Prevention Against Mpox in High-risk Populations During Vaccination Deployment in Colombia
Who cites it
40 citing papers in PubMed, 69 citations in OpenAlex.
- Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults.The Journal of infectious diseases · 2011Trial
- An innovative and stable mRNA-LNP microneedle vaccine elicits humoral and multifunctional cellular immune responses.Acta pharmaceutica Sinica. B · 2026Article
- A review of Mpox: Biological characteristics, epidemiology, clinical features, diagnosis, treatment, and prevention strategies.Exploration (Beijing, China) · 2025Review
- Elucidating the evolution of monkeypox virus genomes through phylo-geo-network and haplogroup analysis.Journal, genetic engineering & biotechnology · 2024Article
- Correlative CD4 and CD8 T-cell immunodominance in humans and mice: Implications for preclinical testing.Cellular & molecular immunology · 2023Article
- Modified vaccinia Ankara-Bavarian Nordic vaccine against mpox in children.The Lancet. Infectious diseases · 2023Article
- A Comprehensive Review on Monkeypox Viral Disease with Potential Diagnostics and Therapeutic Options.Biomedicines · 2023Review
- Human monkeypox infection threat: A comprehensive overview.PLoS neglected tropical diseases · 2023Review
- Potential threat of human pathogenic orthopoxviruses to public health and control strategies.Journal of biosafety and biosecurity · 2023Review
- Insights into monkeypox pathophysiology, global prevalence, clinical manifestation and treatments.Frontiers in immunology · 2023Review
- Prevention of monkeypox with vaccines: a rapid review.The Lancet. Infectious diseases · 2022Review
- Animal Models Used in Monkeypox Research.Microorganisms · 2022Review
- Monkeypox: epidemiology, pathogenesis, treatment and prevention.Signal transduction and targeted therapy · 2022Review
- Evaluating immunogenicity of pathogen-derived T-cell epitopes to design a peptide-based smallpox vaccine.Scientific reports · 2022Article
- Effect of Monkeypox Virus Preparation on the Lethality of the Intravenous Cynomolgus Macaque Model.Viruses · 2022Article
- The outbreak of monkeypox 2022: An overview.Annals of medicine and surgery (2012) · 2022Review
- Monkeypox: the resurgence of forgotten things.Epidemiology and health · 2022Review
- Epicutaneous immunization with modified vaccinia Ankara viral vectors generates superior T cell immunity against a respiratory viral challenge.NPJ vaccines · 2021Article
- Vaccine-related major cutaneous reaction size correlates with cellular-mediated immune responses after tularaemia immunisation.Clinical & translational immunology · 2021Article
- Review
Corrections and comments
- Commented on by
Authors and funding
17 authors at 5 institutions in 5 countries.
Funding
Abstract
The licensed smallpox vaccine, ACAM2000, is a cell culture derivative of Dryvax. Both ACAM2000 and Dryvax are administered by skin scarification and can cause progressive vaccinia, with skin lesions that disseminate to distal sites. We have investigated the immunologic basis of the containment of vaccinia in the skin with the goal to identify safer vaccines for smallpox. Macaques were depleted systemically of T or B cells and vaccinated with either Dryvax or an attenuated vaccinia vaccine, LC16m8. B cell depletion did not affect the size of skin lesions induced by either vaccine. However, while depletion of both CD4(+) and CD8(+) T cells had no adverse effects on LC16m8-vaccinated animals, it caused progressive vaccinia in macaques immunized with Dryvax. As both Dryvax and LC16m8 vaccines protect healthy macaques from a lethal monkeypox intravenous challenge, our data identify LC16m8 as a safer and effective alternative to ACAM2000 and Dryvax vaccines for immunocompromised individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.